jCyte out-licenses rare vision disorder treatment for $252 million
jCell Therapy | Retinitis Pigmentosa | Degenerative Retinal Disorders | jCyte Inc.
jCyte starts second phase of stem cell clinical trial targeting vision loss | The Stem Cellar
EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation - ScienceDirect
Foundation Fighting Blindness - jCyte announced that its emerging cellular therapy for people with retinitis pigmentosa (RP) and related diseases has performed encouragingly in a Phase 2b clinical trial. The treatment is
JCyte signs ex-US licensing deal with Santen for retinal disease therapy
jCyte Inc. Announces Promising Phase 2b Results of jCell Therapy in Retinitis Pigmentosa | Business Wire
Hardy AIM 🎯 on Twitter: "#RENE 🧬 What is a PSC? A Pluripotent Stem Cell Pluripotent Stem Cells hailed a 🔥“big revolution”🔥 for the advancement of cell Therapy 🔥”Miraculous Cells”🔥 Is quite
Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa | California's Stem Cell Agency
Santen Pharmaceutical and jCyte Enter Agreement for jCell Therapy for Retinitis Pigmentosa | OphthalmologyWeb: The Ultimate Online Resource for Ophthalmologists
UCI receives record $592 million in research funding for fiscal 2020-21 | UCI News | UCI
jCyte starts second phase of stem cell clinical trial targeting vision loss | The Stem Cellar
Study outlines use of intravitreal injection of allogeneic human retinal progenitor cells to treat RP
Research focuses on use of intravitreal injection of allogeneic human retinal progenitor cells to treat RP
jCyte Inc. Announces Promising Results In Retinitis Pigmentosa | The Optical Journal
jCyte Shares Encouraging Update on Clinical Trial for Retinitis Pigmentosa | The Stem Cellar
jCyte Inc. Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Business Wire
Comet Creative - jCyte's new website gave the company further credibility to raise capital for a clinical trial. The straight-forward content easily translates the complexity of the firm's retinitis pigmentosa drug research
Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials | Cell Death & Disease
National Science Call - 12/4/2019 — Foundation Fighting Blindness
Stem/progenitor cell-based transplantation for retinal degeneration: a review of clinical trials | Cell Death & Disease
Regenerative Medicine In Ophthalmology
jCell Therapy | Retinitis Pigmentosa | Degenerative Retinal Disorders | jCyte Inc.
ARVO 2018: Dr. Henry Klassen Provides Update on jCyte Stem Cell Trials
Clinical Trials and Natural History Studies for Usher Syndrome
